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BSTRACT
 
Background
 
The combination of cyclophospha-
mide and prednisolone is effective for the treatment
of severe lupus nephritis but has serious adverse ef-
fects. Whether mycophenolate mofetil can be substi-
tuted for cyclophosphamide is not known.
 
Methods
 
In 42 patients with diffuse proliferative lu-
pus nephritis we compared the efficacy and side ef-
fects of a regimen of prednisolone and mycophen-
olate mofetil given for 12 months with those of a
regimen of prednisolone and cyclophosphamide giv-
en for 6 months, followed by prednisolone and aza-
thioprine for 6 months. Complete remission was de-
fined as a value for urinary protein excretion that
was less than 0.3 g per 24 hours, with normal urinary
sediment, a normal serum albumin concentration,
and values for serum creatinine and creatinine clear-
ance that were no more than 15 percent above the
base-line values. Partial remission was defined as a
value for urinary protein excretion that was between
0.3 and 2.9 g per 24 hours, with a serum albumin
concentration of at least 3.0 g per deciliter.
 
Results
 
Eighty-one percent of the 21 patients treat-
ed with mycophenolate mofetil and prednisolone
(group 1) had a complete remission, and 14 percent
had a partial remission, as compared with 76 percent
and 14 percent, respectively, of the 21 patients treat-
ed with cyclophosphamide and prednisolone followed
by azathioprine and prednisolone (group 2). The im-
provements in the degree of proteinuria and the se-
rum albumin and creatinine concentrations were sim-
ilar in the two groups. One patient in each group
discontinued treatment because of side effects. Infec-
tions were noted in 19 percent of the patients in group
1 and in 33 percent of those in group 2 (P=0.29).
Other adverse effects occurred only in group 2; they
included amenorrhea (in 23 percent of the patients),
hair loss (19 percent), leukopenia (10 percent), and
death (10 percent). The rates of relapse were 15 per-
cent and 11 percent, respectively.
 
Conclusions
 
For the treatment of diffuse prolifer-
ative lupus nephritis, the combination of mycophen-
olate mofetil and prednisolone is as effective as a
regimen of cyclophosphamide and prednisolone fol-
lowed by azathioprine and prednisolone. (N Engl J
Med 2000;343:1156-62.)
 
©2000, Massachusetts Medical Society.
 
From the Nephrology Division, Department of Medicine, University of
Hong Kong and Queen Mary Hospital, Hong Kong, China. Address re-
print requests to Dr. T.M. Chan at the Nephrology Division, Department
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Rd., Hong Kong, China, or at dtmchan@hku.hk.
*Other members of the Hong Kong–Guangzhou Nephrology Study
Group are listed in the Appendix.
 
MMUNOSUPPRESSIVE regimens of gluco-
corticoids combined with cytotoxic drugs, par-
ticularly cyclophosphamide, are effective for the
treatment of severe proliferative lupus nephri-
tis.
 
1-3
 
 However, cyclophosphamide has immediate and
cumulative adverse effects, such as marrow suppres-
sion, gonadal toxicity, and hemorrhagic cystitis, and
it is associated with an increased risk of cancer.
Mycophenolic acid, the active metabolite of myco-
phenolate mofetil, selectively suppresses the prolifer-
ation of T and B lymphocytes, the formation of an-
tibodies, and the glycosylation of adhesion molecules
by inhibiting purine nucleotide synthesis and deplet-
ing lymphocytes and monocytes of guanosine triphos-
phate.
 
4
 
 Mycophenolate mofetil is more effective than
azathioprine in preventing acute rejection of renal
allografts.
 
5
 
 Its adverse effects also compare favorably
with those of cyclophosphamide, with gastrointesti-
nal upset being the most common,
 
6
 
 and it has no
mutagenic effects.
 
4
 
 The results of studies in animals
and anecdotal clinical reports suggest that mycophen-
olate mofetil might have a role in the treatment of
patients with lupus nephritis.
 
7-10
 
 We evaluated the ef-
ficacy and safety of mycophenolate mofetil combined
with prednisolone for the treatment of severe lupus
nephritis, as compared with prednisolone combined
first with cyclophosphamide and then with azathio-
prine — a regimen associated with rates of complete
and partial remission of 77 percent and 23 percent,
respectively.
 
11
 
METHODS
 
Patients
 
Between November 1996 and October 1998, we studied 42
patients who had systemic lupus erythematosus according to the
criteria of the American Rheumatism Association, including re-
nal-biopsy evidence of diffuse proliferative lupus nephritis (class
IV according to the World Health Organization’s classification
system),
 
12
 
 urinary protein excretion of 1 g or more per 24 hours,
and a serum albumin concentration of 3.5 g per deciliter or less. Pa-
tients with a serum creatinine concentration higher than 3.4 mg
per deciliter (300 µmol per liter) were excluded, as were those
I
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with life-threatening complications such as cerebral lupus or se-
vere infection, those with a history of poor compliance with drug
regimens, and women who were pregnant or unwilling to use con-
traception. Patients who had received cyclophosphamide within
the previous six months or who had taken oral prednisolone at a
dose of 0.8 mg per kilogram of body weight per day or more for
more than two weeks were also excluded. The study was approved
by the ethics committees of the University of Hong Kong and
the participating hospitals, and all patients gave written informed
consent.
Renal-biopsy specimens were examined by light, immunofluo-
rescence, and electron microscopy, and the findings were catego-
rized according to standard methods.
 
13
 
 Patients whose specimens
showed superimposed membranous changes were included in the
study, provided that there were concomitant diffuse proliferative
features. Investigators who were unaware of the treatment assign-
ments subsequently evaluated the renal-biopsy specimens accord-
ing to indexes of disease activity and chronicity.
 
14
 
Immunosuppressive Treatment and Study Protocol
 
Within 48 hours after undergoing renal biopsy, the patients were
randomly assigned to receive one of two treatments: oral myco-
phenolate mofetil plus oral prednisolone (group 1) or oral cy-
clophosphamide plus oral prednisolone (group 2). The myco-
phenolate mofetil was started at a dose of 1 g twice a day, the
cyclophosphamide at a dose of 2.5 mg per kilogram per day, and
prednisolone at 0.8 mg per kilogram per day. The doses of
mycophenolate mofetil and cyclophosphamide were not changed
during the first six months unless the drugs had adverse effects.
The daily dose of prednisolone was reduced by 5 mg per day ev-
ery two weeks until the dose was 20 mg per day, after which it
was reduced by 2.5 mg per day every two weeks for four weeks
and then by 2.5 mg per day every four weeks, until a maintenance
dose of 10 mg per day had been reached, at approximately six
months. The dose of mycophenolate mofetil was halved at six
months. In group 2, cyclophosphamide was replaced by azathio-
prine (1.5 mg per kilogram per day given orally) at six months.
After 12 months, mycophenolate mofetil was replaced by azathi-
oprine (1 mg per kilogram per day, given orally) in group 1, and
in group 2 the dose of azathioprine was reduced to 1 mg per kil-
ogram per day.
The criteria for the discontinuation of treatment included any
of the following: leukopenia (white-cell count, <2000 per cubic
millimeter), thrombocytopenia (platelet count, <50,000 per cu-
bic millimeter), a hemoglobin concentration of less than 8 g per
deciliter, an increase in the serum creatinine concentration with
or without a concomitant rise in the serum anti–double-stranded
DNA antibody or a fall in the C3 concentration after two weeks
of treatment or failure of the serum anti–double-stranded DNA
antibody to fall or the C3 concentration to rise after four weeks,
a doubling of the serum creatinine concentration, life-threatening
complications (e.g., cerebral lupus or severe infection), pregnan-
cy, severe gastrointestinal upset despite a reduction in the dose of
mycophenolate mofetil (in group 1), or poor compliance. In pa-
tients with mild leukopenia (white-cell count, 2000 to 4000 per
cubic millimeter) or thrombocytopenia (platelet count, 50,000 to
100,000 per cubic millimeter), the dose of mycophenolate mofetil
or cyclophosphamide was halved. Mild gastrointestinal upset in
patients in group 1 was treated by reducing the dose of myco-
phenolate mofetil by 50 percent and then gradually increasing it
by the same amount.
The duration of the study was 12 months. Patients were seen
weekly for four weeks, then every other week for eight weeks, and
then monthly. At each follow-up visit, we evaluated the patients
for clinical manifestations of lupus nephritis and for any adverse
effects of therapy. Blood pressure was measured, urinalysis was
performed, renal and liver function were evaluated, and serum
anti–double-stranded DNA antibodies and serum C3 were meas-
ured. Urinary protein excretion was measured in 24-hour samples
obtained every other week during the first month, then monthly
for 3 months and at 6, 9, and 12 months. Creatinine clearance
was measured at 6 and 12 months. Hypertension was treated with
a calcium-channel blocker, and a beta blocker was added if neces-
sary. The target systolic blood pressure was less than 150 mm Hg
and the target diastolic pressure less than 90 mm Hg. Angioten-
sin-converting–enzyme inhibitors and angiotensin II–receptor
antagonists were not used because of their possible effects on uri-
nary protein and renal function. Prophylaxis with isoniazid (300
mg per day given orally) was prescribed for patients with a history
of clinical or radiologic evidence of tuberculosis.
Complete remission was defined as a value for urinary protein
excretion that was less than 0.3 g per 24 hours, with normal uri-
nary sediment, a normal serum albumin concentration, and values
for both serum creatinine and creatinine clearance that were 15 per-
cent or less above the base-line values. Partial remission was de-
fined as a value for urinary protein excretion that was between 0.3
and 2.9 g per 24 hours, with a serum albumin concentration of
at least 3.0 g per deciliter and stable renal function. Treatment failure
 
*Patients in group 1 received mycophenolate mofetil with prednisolone
for 12 months. Patients in group 2 received cyclophosphamide with pred-
nisolone for six months, followed by azathioprine with prednisolone for six
months. Plus–minus values are means ±SD. P>0.05 for all comparisons
between the two groups.
†The normal range for creatinine is 0.93 to 1.43 mg per deciliter. To
convert the values to micromoles per liter, multiply by 88.4.
‡The normal range for serum albumin is 4.2 to 5.4 g per deciliter.
§The normal range for serum C3 is 60 to 130 mg per deciliter.
¶The normal range for serum anti–double-stranded DNA antibody is
0 to 35 IU per milliliter.
¿The score on the activity index was the sum of the scores (on a scale
of 1 to 3) for endocapillary proliferation, karyorrhexis and fibrinoid necro-
sis (with the score multiplied by 2), cellular crescents (with the score mul-
tiplied by 2), hyaline deposits, leukocyte exudation, and interstitial inflam-
mation.
 
14
 
 Higher scores indicate greater disease activity; the highest possible
score is 24.
**The score on the chronicity index was the sum of the scores (on a
scale of 1 to 3) for glomerular sclerosis, fibrous crescents, tubular atrophy,
and interstitial fibrosis.
 
14
 
 Higher scores indicate greater chronicity; the
highest possible score is 12.
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(N=21)
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 2
(N=21)
 
Sex — M/F 1/20 2/19
Age — yr 36±11 39±9
Duration of lupus — mo 72±69 97±80
Duration of nephritis — mo 54±63 77±76
Organ involvement — no. (%)
Skin
Joint
Serous membrane
13 (62)
15 (71)
5 (24)
9 (43)
12 (57)
5 (24)
Serum creatinine — mg/dl† 1.2±0.6 1.2±0.3
Creatinine clearance — ml/min/1.73 m
 
2
 
of body-surface area
86±35 77±31
Urinary protein excretion — g/24 hr 5.8±4.6 3.7±1.7
Serum albumin — g/dl‡ 2.8±0.6 2.8±0.5
Serum C3 — mg/dl§ 62±34 46±20
Serum anti–double-stranded DNA 
antibody — IU/ml¶
293±204 426±627
Activity score¿ 8.6±2.8 8.6±1.8
Chronicity score** 2.8±1.1 3.9±3.0
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was defined as a value for urinary protein excretion that remained
at or above 3 g per 24 hours or a value of 0.3 to 2.9 g per 24 hours
but with a serum albumin concentration of less than 3.0 g per deci-
liter, an increase in the serum creatinine concentration greater than
or equal to 0.6 mg per deciliter (50 µmol per liter), or a value for
creatinine clearance that was more than 15 percent above the base-
line value, or the discontinuation of treatment due to side effects.
For patients with a complete or partial remission, renal biopsy
was repeated if urinary protein excretion increased by 1 g per 24
hours or more over the base-line value or if there was an increase
in the serum creatinine concentration, irrespective of the value for
the serum anti–double-stranded DNA antibody or C3 concen-
tration. Renal relapse was confirmed by histologic studies. Clini-
cal status was reviewed and categorized at the coordinating center
by personnel who had no knowledge of the treatment assignment.
 
End Points
 
The incidence of complete remission was the primary end point
with respect to efficacy in this study. Predefined secondary end
points included partial remission, adverse effects (including infec-
tions, amenorrhea, and hair loss), a doubling of the serum creati-
nine concentration, a relapse of lupus, and death.
 
Statistical Analysis
 
Serial data were compared within and between groups by re-
peated-measures analysis of variance with one between-group fac-
tor and one repeated-measures factor. Unpaired t-tests were used
for between-group comparisons, and paired t-tests were used for
within-group comparisons. The results are reported as differences
between mean values with 95 percent confidence intervals. The
values for C3, anti–double-stranded DNA antibodies, and creati-
nine were transformed logarithmically before analysis, and the
results are presented as the ratio of geometric means with 95 per-
cent confidence intervals. Categorical groups were compared by
the chi-square test and Fisher’s exact test, as appropriate. McNe-
mar’s test was used for comparisons of dichotomous variables be-
fore and after treatment. All statistical tests were two-sided.
 
RESULTS
 
There were 21 patients in each group. In 16 of the
patients in group 1 and in 13 of those in group 2,
the diagnosis of systemic lupus erythematosus was
new. The base-line characteristics of the patients in
the two groups were similar (Table 1). A total of 29
patients (69 percent) had low serum C3 concentra-
tions, and 35 (83 percent) had high serum anti–dou-
ble-stranded DNA antibody concentrations. Twelve
patients (7 in group 1 and 5 in group 2) had high
serum creatinine concentrations (P=0.50), and 15
(8 in group 1 and 7 in group 2) had a creatinine clear-
 
Figure 1.
 
 Mean (±SD) Serum C3 and Creatinine Concentrations in Patients with Diffuse Proliferative
Lupus Nephritis Who Were Treated with Mycophenolate Mofetil and Prednisolone (Group 1) or with
Cyclophosphamide and Prednisolone Followed by Azathioprine and Prednisolone (Group 2).
In both groups, the mean serum C3 concentration after two weeks of therapy was significantly higher
than the base-line value, and it remained significantly higher at each subsequent evaluation (P<0.05
for all comparisons between base-line and follow-up in each group). The mean serum creatinine con-
centration was significantly lower than the base-line value after 2 weeks of therapy in group 2 and
after 12 weeks of therapy in group 1, and it remained significantly lower at each subsequent evaluation
(P<0.05). The numbers below the panels are numbers of patients for whom data were available. To
convert the values for creatinine to micromoles per liter, multiply by 88.4.
0.0
1.5
0 12
1.0
0.5
963
Months
S
er
u
m
 C
re
at
in
in
eJ
(m
g
/d
l)
NO. OF PATIENTS
Group 1
Group 2
21
21
20
20
20
20
20
17
17
16
Group 1
Group 2
0
140
20
40
60
80
100
120
S
er
u
m
 C
3 
(m
g
/d
l)
Group 1
Group 2
Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on January 23, 2007 . 
 EFFICACY OF MYCOPHENOLATE MOFETIL IN PATIENTS WITH DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS
 
Volume 343 Number 16
 
·
 
1159
 
Figure 2.
 
 Mean (±SD) Serum Albumin Concentration and Urinary Protein Excretion in Patients with
Diffuse Proliferative Lupus Nephritis Who Were Treated with Mycophenolate Mofetil and Prednisolone
(Group 1) or with Cyclophosphamide and Prednisolone Followed by Azathioprine and Prednisolone
(Group 2).
The mean serum albumin concentration was significantly higher than the base-line value after two
weeks of therapy in group 2 and after four weeks of therapy in group 1, and it remained significantly
higher at each subsequent evaluation (P<0.05 for the comparisons in each group). Urinary protein ex-
cretion was significantly lower than the base-line value after two weeks of therapy in group 1 and after
four weeks of therapy in group 2, and it remained significantly lower at each subsequent evaluation
(P<0.05 for the comparisons in each group). The numbers below the panels are numbers of patients
for whom data were available.
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ance that was less than 80 ml per minute per 1.73 m
 
2
 
of body-surface area (P=0.75). Diffuse membranous
deposits were noted in biopsy specimens from three
patients in each group.
 
Outcome of Treatment
 
The mean serum C3 concentration increased sig-
nificantly in both groups after two weeks of treat-
ment (Fig. 1). The proportion of patients with low se-
rum C3 concentrations was reduced from 57 percent
at base line to 10 percent at eight weeks in group 1
(P=0.002) and from 90 percent to 57 percent in
group 2 (P=0.01); the proportion of patients with
high serum anti–double-stranded DNA antibody con-
centrations was reduced from 81 percent to 10 per-
cent in group 1 (P=0.001) and from 76 percent to
52 percent in group 2 (P=0.03). The differences
between the proportions of patients with abnormal
values in the two groups at eight weeks were not sig-
nificant.
Serial values for serum C3, albumin, and creati-
nine concentrations and for urinary protein excretion
were similar in the two groups (Fig. 1 and 2), as were
the concentrations of anti–double-stranded DNA an-
tibody. The mean serum creatinine concentration de-
creased after 2 weeks of treatment in group 2 (ratio
of geometric mean at base line to geometric mean
at two weeks, 1.1; 95 percent confidence interval,
1.0 to 1.2; P=0.04) and after 12 weeks of treatment
in group 1 (ratio of geometric mean, 1.1; 95 percent
confidence interval, 1.0 to 1.2; P=0.03). Urinary
protein excretion decreased and the serum albumin
concentration increased within four weeks in both
groups. At 12 months, creatinine clearance did not
differ significantly from the base-line value in either
group, and the earlier improvements in urinary pro-
tein excretion and the serum C3, albumin, and cre-
atinine concentrations were sustained; all these val-
ues were similar in the two groups (Table 2). At 12
months, none of the patients had a serum creatinine
Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on January 23, 2007 . 
 1160
 
·
 
October 19, 2000
 
The New England Journal  of  Medicine
 
concentration that was more than 15 percent above
the base-line value.
The incidence of complete or partial remission and
the duration of treatment before a complete remission
was achieved were similar in the two groups (Table
3). The base-line characteristics of the patients who
subsequently had a complete or partial remission
were similar, including the values for the activity in-
dex and the chronicity index. All the patients with a
partial remission had a base-line value for urinary pro-
tein excretion that was higher than 3.0 g per 24 hours
(range, 3.1 to 20.2). At four weeks, the mean (±SD)
 
*Patients in group 1 received mycophenolate mofetil with prednisolone for 12 months. Patients in
group 2 received cyclophosphamide with prednisolone for six months, followed by azathioprine with
prednisolone for six months. Values for serum albumin, urinary protein excretion, and creatinine
clearance are means ±SD, with the difference between the values at base line and 12 months given.
Values for serum C3 and creatinine are geometric means, with the ratio of the base-line value to the
value at 12 months given. P>0.05 for all comparisons between group 1 and group 2. CI denotes
confidence interval.
†To convert the values for creatinine to micromoles per liter, multiply by 88.4.
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(95% CI)
P
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Serum C3 (mg/dl)
Group 1
Group 2
54.1
46.4
93.1
85.7
0.58 (0.6 to 0.8)
0.54 (0.5 to 0.6)
0.001
<0.001
Serum albumin (g/dl)
Group 1
Group 2
2.8±0.6
2.8±0.5
4.0±0.4
4.1±0.3
1.2±0.6 (0.8 to 1.4)
1.3±0.4 (1.0 to 1.5)
<0.001
<0.001
Serum creatinine (mg/dl)†
Group 1
Group 2
1.13
1.10
0.97
0.99
1.16 (1.04 to 1.37)
1.11 (1.06 to 1.38)
0.02
0.01
Urinary protein excretion (g/24 hr)
Group 1
Group 2
5.8±4.6
3.7±1.7
0.5±1.1
0.2±0.3
¡5.3±2.4 (¡2.4 to ¡6.3)
¡3.5±1.1 (¡2.4 to ¡4.1)
<0.001
<0.001
Creatinine clearance (ml/min/1.73 m
 
2
 
)
Group 1
Group 2
86±35
77±31
92±21
82±39
6±28 (¡15 to 18)
5±37 (¡22 to 11)
0.15
0.18
*Patients in group 1 received mycophenolate mofetil with prednisolone for 12 months. Patients in group 2 received
cyclophosphamide with prednisolone for six months, followed by azathioprine with prednisolone for six months. Plus–
minus values are means ±SD. CI denotes confidence interval.
†The difference is shown as the value for group 1 minus the value for group 2.
‡Data were available for 20 patients in group 1 and 19 in group 2.
§Values are for individual patients. The difference between the groups is the mean value.
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†
P
VALUE
no. % (95% CI) no. % (95% CI) % (95% CI)
Complete remission 17 81 (58 to 95) 16 76 (53 to 92) 5 (¡20 to 30) 1.00
Partial remission 3 14 3 14 0 (¡21 to 21) 1.00
Treatment failure 1 5 2 10 ¡5 (¡20 to 11) 1.00
Relapse‡ 3 15 2 11 4 (¡16 to 25) 1.00
Discontinuation of treatment 1 5 1 5 0 (¡13 to 13) 1.00
Death 0 2 10 ¡10 (¡22 to 3) 0.49
wk after diagnosis wk (95% CI)
Time to complete remission 17±11 22±11 ¡5 (¡13 to 2) 0.15
Time to partial remission 16±14 14±3 2 (¡28 to 32) 0.81
Time to relapse§ 37, 42, 42 36, 42 1.3 (¡8.5 to 11.2) 0.70
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value for urinary protein excretion was 2.4±2.0 g per
24 hours in the group of patients who had a com-
plete remission and 5.1±3.1 g per 24 hours in the
group with a partial remission, a difference of 2.7 g per
24 hours (95 percent confidence interval, 0.7 to 4.7;
P=0.01). After four months of treatment, the serum
albumin concentration was 3.8±0.4 g per deciliter
in the complete-remission group and 3.2±0.8 g per
deciliter in the partial-remission group, a difference
of 0.6 g per deciliter (95 percent confidence inter-
val, 0.2 to 1.0; P=0.01).
Of the 39 patients who had a complete or partial
remission, 3 (15 percent) in group 1 and 2 (11 per-
cent) in group 2 had relapses (Table 3), which oc-
curred after nine months, when the patients were
receiving maintenance immunosuppressive therapy.
Repeated biopsy revealed focal proliferative lupus ne-
phritis in two patients, diffuse proliferative lupus ne-
phritis in one patient, and membranous lupus nephri-
tis in two patients.
Cessation of Treatment and Adverse Effects
Treatment was discontinued prematurely in two pa-
tients: one in group 1 at three weeks because of di-
arrhea and one in group 2 at four weeks because of
leukopenia. In addition, one patient in group 2 died
at 11 weeks without having had a response to treat-
ment. The study treatment was classified as having
failed in these three patients. Leukopenia (white-cell
count, «4000 per cubic millimeter) occurred in two
patients in group 2, in one of whom treatment was
discontinued. The condition of the other patient
improved after the dose of cyclophosphamide was
reduced. Infections developed in 11 patients (26 per-
cent), with a similar incidence in the two groups (Ta-
ble 4); 3 of the 6 episodes (50 percent) in group 1
and 6 of the 10 episodes (60 percent) in group 2 ne-
cessitated hospitalization. One episode of pneumonia,
in a patient in group 2, was associated with leukope-
nia. One patient in group 1 had severe diarrhea. There
were no significant differences in the incidence of hair
loss or amenorrhea between the two groups. Two pa-
tients (both in group 2) died during the study: one
from miliary tuberculosis and the adult respiratory dis-
tress syndrome at 11 weeks and the other from cerebral
hemorrhage, which was unrelated to thrombocytope-
nia or hypertension, at 28 weeks.
DISCUSSION
Data from the National Institutes of Health have
shown that patients with lupus nephritis who are treat-
ed with glucocorticoids and a prolonged course of
cytotoxic agents have better long-term renal function
than those treated with glucocorticoids alone.15 Ac-
tive lupus is characterized by the activation of lym-
phocytes and the production of autoantibodies. Un-
like cyclophosphamide, which is a nonspecific cytotoxic
drug, mycophenolate mofetil suppresses lymphocyte
proliferation selectively because of the dependence
of these cells on purine nucleotide synthesis. The ef-
fect of mycophenolate mofetil in depleting lympho-
cytes of guanosine triphosphate and suppressing gly-
cosylation of adhesion molecules may provide an
additional clinical benefit.4
Optimal treatment of lupus nephritis entails rapid
induction of remission, effective prophylaxis against
relapse, and prevention of renal failure. Progressive
renal failure, a common end point in previous stud-
ies, has been reported in up to 25 percent of patients
within five years after diagnosis, even after treatment
with prednisolone and intravenous cyclophospha-
mide.2,3,15 Indeed, treatment-related differences in rates
of renal failure may not be discernible early in the
course of treatment. We therefore chose complete
remission as the primary end point in our one-year
study, since the purpose of the study was to compare
the efficacy of the immunosuppressive regimens in
controlling acute disease activity. Control of disease
activity is important in order to preserve functional
renal tissue and prevent renal failure. We defined com-
plete remission strictly, as the normalization of val-
ues for urinary protein excretion, urinary sediment,
and serum albumin and a stable serum creatinine con-
centration. The long-term renal outcome represents
the additive effect of multiple confounding factors,
including the efficacy of immunosuppressive therapy;
preexisting renal reserve and scarring; the number,
severity, and treatment of subsequent relapses of ne-
phritis; and the adequacy of blood-pressure control.
*Patients in group 1 received mycophenolate mofetil with prednisolone
for 12 months. Patients in group 2 received cyclophosphamide with pred-
nisolone for six months, followed by azathioprine with prednisolone for six
months. With the exception of the number of episodes and type of infec-
tion, numbers refer to numbers of patients.
†Data were available for 6 patients in group 1 and 10 in group 2.
‡There were 15 premenopausal patients in group 1 and 13 in group 2.
TABLE 4. ADVERSE EFFECTS.*
ADVERSE EFFECT
GROUP 1
(N=21)
GROUP 2
(N=21)
P
VALUE
no. % (95% CI) no. % (95% CI)
Infection
No. of episodes
Type
Respiratory infection†
Tuberculosis
Urinary tract infection
Herpes zoster
4
6
4
0
0
2
19 (5–42)
67
33
7
10
5
1
2
2
33 (15–57)
50
10
20
20
0.29
0.45
0.63
1.00
0.50
0.60
Other
Leukopenia
Hair loss
Amenorrhea‡
Transient
Permanent
Diarrhea
0
0
0
0
0
1 5
2
4
3
2
1
0
10
19
23
15
8
0.49
0.11
0.09
0.21
0.46
1.00
Death 0 2 10 0.49
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With regard to the last factor, we made sure that
blood-pressure control was satisfactory and similar
in the two treatment groups.
We found that the regimen of mycophenolate mofe-
til and prednisolone induced complete remission in
81 percent of patients and partial remission in 14
percent within 12 months. These results were similar
to those obtained with our sequential regimen but
were better than the response rates reported by oth-
er investigators.2,3 The more favorable response in
our study may be attributable to earlier diagnosis
and treatment, as evidenced by the lower indexes of
chronicity.11 Whether a patient had a complete or
partial remission was not related to base-line charac-
teristics, except that all patients with partial remis-
sion had nephrotic-range proteinuria at base line.
Improvements in urinary protein excretion, serum
albumin concentrations, and renal function were sus-
tained at 12 months, and none of the patients had a
deterioration in renal function, which might precede
progressive renal failure on more prolonged follow-
up. In view of the severe disease in our patients, as
indicated by a mean disease-activity score of 8.6 and
the fact that 29 percent of the patients had abnormal
serum creatinine concentrations, the results of treat-
ment with mycophenolate mofetil compare favor-
ably with those of conventional therapies.
With regard to side effects, severe diarrhea devel-
oped in only one patient treated with mycopheno-
late mofetil, and the incidence of infection was sim-
ilar in the two treatment groups. These results suggest
that mycophenolate mofetil is easier to tolerate than
cyclophosphamide, since hair loss, amenorrhea, and
death occurred only in the group of patients treated
with cyclophosphamide.
Fifteen percent of the patients treated with myco-
phenolate mofetil had a relapse within the first year.
Although this rate of relapse was similar to the rate
in group 2 and the rate among patients treated with
intravenous cyclophosphamide for six months,2 the
sample in our study was too small for a meaningful
evaluation of differences. In view of the fact that my-
cophenolate mofetil is tolerable and not mutagenic,
a higher maintenance dose (e.g., 1.5 g per day) might
reduce the risk of relapse.
We conclude that mycophenolate mofetil combined
with prednisolone is an effective treatment for pa-
tients with diffuse proliferative lupus nephritis, with
results and toxicity that are similar to those of treat-
ment with cyclophosphamide followed by azathio-
prine. 
Supported by the Lee Wing Tat Renal Research Fund and the Nephrology
Research Fund of the University of Hong Kong. Roche Pharmaceuticals
supplied the mycophenolate mofetil used in this study.
APPENDIX
Other members of the Hong Kong–Guangzhou Nephrology Study
Group are as follows: University of Hong Kong and Queen Mary Hospital,
Hong Kong, China — S.C.W. Tang, L.S.L. Lui, M.F. Lam, C.C.K. Ho, and
C.C. Mok; Sun Yat Sen University of Medical Sciences First Affiliated Hos-
pital, Guangzhou, China — Z.P. Jiang, Y.J. Li, T. Jang, R.G. Ye, and X.Q.
Yu; Kwong Wah Hospital, Hong Kong, China — S.K. Mak; and Princess
Margaret Hospital, Hong Kong, China — W.K. Tsang.
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